AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33597131
Drug: ESH/ESC 2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESH/ESC 2013 guideline recommendation for antihypertensive medication
Trial: 33597131
Drug: ESC/ESH 2018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESC/ESH 2018 guideline recommendation for antihypertensive medication
Trial: 33597131
Drug: WHO/ISH 2003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO/ISH 2003 guideline recommendation for antihypertensive medication
Trial: 33597131
Drug: ISH 2020
RxNorm normalized name: ALCOHOL 45 mL in 60 mL EXTRACORPOREAL GEL [ishine hand sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISH 2020 guideline recommendation for antihypertensive medication
Trial: 32246196
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of psychoeducation and cognitive behavioral therapy (CBT)
Trial: 32246196
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of psychoeducation and CBT
Trial: 33720588
Drug: Polydexa with
RxNorm normalized name: Lydexa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polydexa with phenylephrinum (topical nasal spray)
Trial: 33720588
Drug: Systemic antibacterial
RxNorm normalized name: Trimethoprim and derivatives, systemic antibacterials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibacterial therapy and long‐acting local decongestants
Trial: 33823786
Drug: Group TAP
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group TAP (20 mL of 0.5% ropivacaine per side)
Trial: 34862870
Drug: Amiodarone combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone combined with atorvastatin
Trial: 35411186
Drug: Low Serratus
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Serratus Anterior Plane Block (SAPB) with 40 mL 0.375% ropivacaine
Trial: 35413933
Drug: HCV self-testing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV self-testing via online distribution (oral fluid- or blood-based HCV self-test kit mailed)
Trial: 35413933
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (clinic-based HCV antibody testing)
Trial: 36005503
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day SXRG84 for six weeks
Trial: 36005503
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day SXRG84 for six weeks
Trial: 36005503
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for six weeks followed by 2 g/day SXRG84 for six weeks (Study 2)
Trial: 34654349
Drug: ZSP1273 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1273 (single or multiple doses)
Trial: 32240370
Drug: Parent Child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent Child Interaction Therapy Emotion Development (PCIT-ED)
Trial: 34628482
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg JNJ-48816274
Trial: 34628482
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg JNJ-48816274
Trial: 32658921
Drug: Cryotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy treatment for hrHPV positive women
Trial: 32658921
Drug: Provider perceptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provider perceptions of barriers to treatment
Trial: 32658921
Drug: Facilitators of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitators of treatment
Trial: 34336894
Drug: Anaprazole 20
RxNorm normalized name: pantoprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaprazole 20 mg
Trial: 34336894
Drug: Anaprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaprazole 40 mg
Trial: 32987282
Drug: Symptom severity
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom severity (self- and rater assessed at beginning and end of therapy)
Trial: 33784487
Drug: FitSkills exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FitSkills exercise program (12 weeks, twice-weekly sessions)
Trial: 35035429
Drug: Lipid based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid based nutritional supplement for pregnant and lactating women LNS-PLW
Trial: 35614509
Drug: Multicomponent LIVE
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent LIVE intervention (including medication review by the PwD’s regular GPs)
Trial: 34889235
Drug: modified GGQL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified GGQL formula plus basic antitumor therapy
Trial: 34889235
Drug: basic antitumor
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: basic antitumor therapy
Trial: 34197772
Drug: Emtricitabine and
RxNorm normalized name: emtricitabine and tenofovir alafenamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine and tenofovir alafenamide (200/25 mg)
Trial: 34197772
Drug: Emtricitabine and
RxNorm normalized name: emtricitabine and tenofovir alafenamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine and tenofovir disoproxil fumarate (200/300 mg)
Trial: 33017685
Drug: Retrograde filling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrograde filling of the bladder with 200 mL of saline before catheter removal
Trial: 32856785
Drug: Postoperative concurrent
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative concurrent aerobic and resistance training for 12 weeks
Trial: 36079794
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day n3-PUFA
Trial: 35598544
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of saccharin
Trial: 35598544
Drug: 300 ml
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ml of water
Trial: 35657320
Drug: ctDNA-positive patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ctDNA-positive patients receiving adjuvant chemotherapy
Trial: 35657320
Drug: ctDNA-negative patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ctDNA-negative patients not receiving adjuvant chemotherapy
Trial: 35487736
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of light acupuncture treatment and five-element music therapy
Trial: 35487736
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment group
Trial: 36153330
Drug: TAK-653 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-653 0.5 mg
Trial: 36153330
Drug: TAK-653 6
RxNorm normalized name: TAK-653
DrugBank: TAK-653 (DB16304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-653 6 mg
Trial: 33433363
Drug: Anticipated delay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticipated delay in help-seeking for rectal bleeding
Trial: 35210132
Drug: 14 mg
RxNorm normalized name: iodine 0.14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg lenvatinib plus everolimus 5 mg/d
Trial: 35210132
Drug: 18 mg
RxNorm normalized name: niacin 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg lenvatinib plus everolimus 5 mg/d
Trial: 33626290
Drug: Dengue vaccine
RxNorm normalized name: Dengue vaccine
DrugBank: Dengue tetravalent vaccine, live (DB14764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue vaccine booster
Trial: 35797300
Drug: Permethrin 5%
RxNorm normalized name: PERMETHRIN 5% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permethrin 5% and Fusidic acid 2% cream
Trial: 34054104
Drug: 4‐μg E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐μg E2 vaginal insert
Trial: 34054104
Drug: 10‐μg E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐μg E2 vaginal insert
Trial: 32762415
Drug: Pembrolizumab (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (first-line treatment)
Trial: 35641166
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) transplantation of mesenchymal stem cells (MSC)
Trial: 34377204
Drug: Intravenous eptifibatide
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous eptifibatide before angioplasty with heparin
Trial: 34377204
Drug: Coronary angioplasty
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary angioplasty with heparin
Trial: 36034460
Drug: LH-based modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH-based modified GnRH antagonist protocol
Trial: 36034460
Drug: Conventional flexible
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional flexible GnRH antagonist protocol
Trial: 33238932
Drug: Mindfulness oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness oriented intervention (6 weeks of mindfulness training combined with interactive drug education)
Trial: 34755786
Drug: Chincup (CC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chincup (CC)
Trial: 33050586
Drug: 320 mg
RxNorm normalized name: aspirin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg of Fermented Porcine Placental Extract (FPP) once daily
Trial: 34117637
Drug: Study medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study medication (specifics not provided)
Trial: 35636937
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of melatonin prolonged-release oral capsules
Trial: 32689975
Drug: Bictegravir/Emtricitabine/Tenofovir Alafenamide
RxNorm normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) single tablet regimen
Trial: 32689975
Drug: Boosted protease-inhibitor
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boosted protease-inhibitor (bPI) regimen
Trial: 33444178
Drug: 8-week group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week group art therapy intervention
Trial: 36027380
Drug: Short-acting RAS
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting RAS blockers taken on awakening
Trial: 36027380
Drug: Short-acting RAS
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting RAS blockers taken at bedtime
Trial: 37759290
Drug: Automated Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated Insulin Delivery (AID) devices
Trial: 33884645
Drug: Trophic enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trophic enteral feeding (20 ml/h) via a nasogastric tube, in addition to standard care.
Trial: 33884645
Drug: Standard nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nutrition care (parenteral nutrition).
Trial: 35720885
Drug: Laparoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic treatment (observation group)
Trial: 35720885
Drug: Open surgical
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open surgical treatment (control group)
Trial: 32648508
Drug: PDE‐5 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDE‐5 inhibitors (PDE‐5i)
Trial: 32648508
Drug: No PDE‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No PDE‐5 inhibitors (no PDE‐5i)
Trial: 36447250
Drug: Action Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action Observation Therapy (AOT) combined with eccentric exercises
Trial: 35659064
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg oleoylethanolamide (OEA) capsule daily for 8 weeks
Trial: 35659064
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg capsule containing wheat flour (placebo) daily for 8 weeks
Trial: 34045217
Drug: Medication review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication review at hospital discharge combined with communication stimulus between hospital physicians and general practitioners
Trial: 32237922
Drug: Cranberry supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry supplement (288 mg equivalent to 26 g of dried cranberry)
Trial: 35320892
Drug: Durvalumab 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1,500 mg q4w + Pegylated liposomal doxorubicin (PLD) or Topotecan or Weekly Paclitaxel (arm 3)
Trial: 35320892
Drug: Durvalumab 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1,500 mg q4w + Tremelimumab 75mg q4w + PLD or Topotecan or Weekly Paclitaxel (arm 4)
Trial: 35320892
Drug: Durvalumab 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1,500 mg q4w + Tremelimumab 300mg [1 dose] + Weekly Paclitaxel [60 mg/m² D1,8,15 q4w for 4 cycles] (arm 5)
Trial: 37850681
Drug: Anti-seizure medications
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-seizure medications
Trial: 35114331
Drug: Standard Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Oral Hygiene Advice (OHA) with intra-oral camera (IOC) images
Trial: 35114331
Drug: Standard Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Oral Hygiene Advice (OHA)
Trial: 34158427
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 15 mg/kg (Group M)
Trial: 35970278
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of IV tranexamic acid preoperatively
Trial: 33991337
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of diesel exhaust particles (DEP) at nontoxic concentrations
Trial: 33991337
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of an antioxidant mixture
Trial: 35054157
Drug: Liposomal fat-soluble
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal fat-soluble vitamin formulation containing vitamin K2 (2667 IU vitamin A, 1333 IU beta-carotene, 4000 IU D3, 150 IU E, 2 mg K1, 400 μg K2)
Trial: 35054157
Drug: Liposomal fat-soluble
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal fat-soluble vitamin formulation containing vitamin K2
Trial: 35054157
Drug: Standard vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard vitamin preparations (2500 IU vitamin A, 1428 IU beta-carotene, 4000 IU D3, 150 IU E, 2.14 mg K1)
Trial: 33049119
Drug: Nebulized ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized ipratropium bromide (500 µg in 0.9% saline per dose)
Trial: 33185345
Drug: Sildenafil spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil spray (50 mg) on an empty stomach
Trial: 33185345
Drug: Sildenafil tablet
RxNorm normalized name: Sildenafil Tablets
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil tablet (50 mg) on an empty stomach
Trial: 33185345
Drug: Sildenafil spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil spray (50 mg) after a meal
Trial: 33185345
Drug: Sildenafil tablet
RxNorm normalized name: Sildenafil Tablets
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil tablet (50 mg) after a meal
Trial: 33420114
Drug: 2-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose regimen of hepatitis A vaccine (0, 6 months)
Trial: 33420114
Drug: 3-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose regimen of hepatitis A vaccine (0, 1, 6 months)
Trial: 32368869
Drug: Lenabasum (cannabinoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenabasum (cannabinoid type 2 receptor agonist)
Trial: 33690245
Drug: Fully automated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully automated pulsating support system air mattress used for 30 days in the treatment group (n = 18)
Trial: 36173596
Drug: Colchicine (1-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1-1.5 mg/day for 3 days, then 0.5 mg/day for 11 days) and Prednisone (60 mg/day for 3 days)
Trial: 36173596
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (intravenous dexamethasone)
Trial: 35361560
Drug: Intermittent fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent fasting (water-only 24-h fasting twice-per-week for 4 weeks and once-per-week for 22 weeks)
Trial: 32659313
Drug: DBV712 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBV712 250 μg (epicutaneous immunotherapy)
Trial: 36807273
Drug: Conventional drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug-eluting stent (DES)
Trial: 33634616
Drug: 0.8% HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8% HA gel
Trial: 34694643
Drug: Placebo tendoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tendoscopic treatment
Trial: 33220329
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g MCT/day
Trial: 33220329
Drug: 18 g
RxNorm normalized name: flotufolastat F 18 gallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 g MCT/day
Trial: 33220329
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 g MCT/day)
Trial: 33220329
Drug: MCT (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT (12 g and 18 g)
Trial: 32002593
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg adrenaline via intraosseous route
Trial: 32002593
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg adrenaline via intravenous route
Trial: 34489390
Drug: Extended-field IMRT
RxNorm normalized name: ZINC OXIDE 17.8 g in 100 mL TOPICAL LOTION [Fieldtrip - Whatever the Weather Daily Moisturizer Zinc Oxide Sunscreen - SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-field IMRT with chemotherapy
Trial: 34489390
Drug: Pelvic-field IMRT
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic-field IMRT with chemotherapy
Trial: 36171582
Drug: Hydrocortisone 200
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 200 mg daily, vitamin C 2 g every 6 hours, thiamine 200 mg every 12 hours
Trial: 33185364
Drug: Subcutaneous semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous semaglutide 0.1 mg
Trial: 33185364
Drug: Subcutaneous semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous semaglutide 0.2 mg
Trial: 33185364
Drug: Subcutaneous semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous semaglutide 0.4 mg
Trial: 32444056
Drug: Diphenhydramine solution
RxNorm normalized name: diphenhydramine Oral Solution
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenhydramine solution (DS)
Trial: 32515694
Drug: PIV ≤
RxNorm normalized name: Piperacillin/tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIV ≤ 7 mL (25th percentile)
Trial: 32515694
Drug: PIV ≥
RxNorm normalized name: Piperacillin/tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIV ≥ 72 mL (75th percentile)
Trial: 32515694
Drug: Pre-treatment factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment factors for small-PIV/mRS ≥ 3
Trial: 32515694
Drug: Post-treatment factors
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment factors for small-PIV/mRS ≥ 3
Trial: 32859308
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (ESPEN)
Trial: 32859308
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (ASPEN)
Trial: 35778995
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia (LIA) using ropivacaine, epinephrine, ketorolac, and normal saline solution.